Search
A well-attended second meeting from the European Hematology Association (EHA) and the EHA Scientific Working Group on Red Cell and Iron
For the second time the European Hematology Association (EHA) and the EHA Scientific Working Group on Red Cell and Iron joined in the organization of the meeting focused on Red Cell and Iron Metabolism Defects: From basic science to clinical…
Read moreHighlights of Past EHA (HOPE) Middle East and North Africa (MENA) 2021 - report
The sixth HOPE MENA, with highlights of the EHA Annual Congress, successfully concluded September 23-24. Fully virtual for the second year in a row, the program was compiled together with eight regional partner societies.
Read moreConnecting experts on inherited anemias and iron defects in Budapest
October 12-14, 2023 – Budapest, Hungary
Meeting Chairs:
Ali Taher, American University of Beirut Medical Center, Beirut, Lebanon
Achille Iolascon, University Federico II of Naples, Naples, Italy
In October 2023 EHA and the Specialized Working Group (SWG) on Red Cell and Iron hosted a…
Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.
Read moreMajor bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).